Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-527 in Subjects With Moderate COVID-19

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 10 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bemnifosbuvir (Primary)
Indications COVID-19 respiratory infection
Focus Therapeutic Use
Sponsors Atea Pharmaceuticals

Most Recent Events

08 Aug 2022 According to an Atea pharmaceuticals media release, final results from this trial were presented in May.
17 May 2022 Status changed from recruiting to discontinued early due to evolving COVID-19 standard of care.
10 May 2022 According to an Atea pharmaceuticals media release, Atea plans to present the full results of this study at an upcoming scientific meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com